Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992 Jun;2(2):149-55.
doi: 10.1016/0924-977x(92)90025-4.

Double-blind Cross-Over Study of Phosphatidylserine vs. Placebo in Patients With Early Dementia of the Alzheimer Type

Affiliations
Clinical Trial

Double-blind Cross-Over Study of Phosphatidylserine vs. Placebo in Patients With Early Dementia of the Alzheimer Type

R R Engel et al. Eur Neuropsychopharmacol. .

Abstract

Thirty-three patients with mild primary degenerative dementia according to DSM-III (MMS between 15 and 27) took part in a double-blind cross-over study of phosphatidylserine (Fidia, 300 mg/d) versus placebo. Both treatment phases lasted for 8 weeks with an 8 week washout phase in between and a 4 week washout phase before treatment phase one. Clinical global improvement ratings showed significantly more patients improving under BC-PS than under placebo during treatment phase one. The improvement carried over to the following wash-out and treatment phases. There were no significant improvements in GBS dementia rating scale, psychometric tests or P300-latency. 16-channel EEG mapping findings indicated that the patients initially showed higher power values in all frequency bands (except alpha), when compared to a younger, healthy control group. BC-PS reduced the higher power values compared to placebo, shifting EEG power more towards the normal level.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

Publication types

Substances

LinkOut - more resources

Feedback